BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24598651)

  • 1. [Early monitoring drug-resistance of patients with BCR/ABL(+) ALL by DCDF-FISH].
    Xu F; Zhang ZL; Luan SQ; Wen F; Kong YY; Wan LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):54-7. PubMed ID: 24598651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Signal Patterns of Dual Color Dual Fusion Fluorescence in Situ Hybridization for Detection of Genetic Abnormality in Adult Patients with ALL and Their Clinical Application].
    Jiang M; Zhang ZL; Xin YH; Liu SY; Li X; Wan LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):375-80. PubMed ID: 27150995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring of bcr/abl fusion gene by interphase-dual-color and dual-fusion fluorescence in situ hybridization in CML after allo-HSCT].
    Qian SX; Li JY; Zhang R; Hong M; Qiu HR; Li L; Xu W; Sheng RL; Wu HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):577-81. PubMed ID: 16800946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison and significance of DCDF probe and ES probe in the detection of BCR/ABL fusion gene].
    DU QH; YING Y; CHEN XY; LI QS; WANG SQ; MO WJ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Apr; 28(2):220-2. PubMed ID: 21462140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
    Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.
    Primo D; Tabernero MD; Rasillo A; Sayagués JM; Espinosa AB; Chillón MC; Garcia-Sanz R; Gutierrez N; Giralt M; Hagemeijer A; San Miguel JF; Orfao A
    Leukemia; 2003 Jun; 17(6):1124-9. PubMed ID: 12764379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of bcr/abl fusion gene and its derivative chromosome 9 deletions in CML by using home-made bcr/abl extra-signal probe].
    Lai YY; Feng L; Wang Z; Lü S; Dang H; Shi Y; He Q; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):199-203. PubMed ID: 20137147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of Bcr/Abl gene rearrangement in chronic myelogenous leukemia patients by dual-color dual-fusion fluorescence in situ hybridization].
    Guo B; Zhu HL; Li SX; Lu XC; Fan H; Zhao DD; Han XP; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):261-5. PubMed ID: 19379547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis and identification of variant Ph chromosome translocation in patients with chronic myelogenous leukemia by conventional cytogenetics and fluorescence in situ hybridization].
    Liu XP; Liu SH; Li CW; Bo LJ; Qin S; Dai Y; Qian LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):298-303. PubMed ID: 15228654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Home-brew" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.
    Albano F; Anelli L; Zagaria A; Archidiacono N; Liso V; Specchia G; Rocchi M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):121-6. PubMed ID: 17452253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of BCR/ABL fusion gene by fluorescence in situ hybridization and its clinical application].
    Zhou RL; Mo YX; Lan M; Lin JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1283-8. PubMed ID: 22040989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
    Grand FH; Chase A; Iqbal S; Nguyen DX; Lewis JL; Marley SB; Davidson RJ; Goldman JM; Gordon MY
    Genes Chromosomes Cancer; 1998 Oct; 23(2):109-15. PubMed ID: 9739013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.